Evidence map›Paper›PMID 28233803›Full record

ReviewNature reviews. Cancer2017

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Jonathan C M Wan, Charles Massie, Javier Garcia-Corbacho, Florent Mouliere, James D Brenton, Carlos Caldas, Simon Pacey, Richard Baird, Nitzan Rosenfeld

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,533 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,533citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04178889 unknown statusnot on this mapstarted 2020, after this paper: background citation

Second Primary Lung Cancer Cohort Study (SPORT)

TypeobservationalSponsorPapworth Hospital NHS Foundation TrustRan2020 to 2024Enrolled850ConditionsLung Cancer
NCT07391007 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Multidimensional Early-Recurrence Risk Stratification System and Personalized Treatment for Colorectal Cancer Liver Metastases: A Prospective Clinical Study

Typeobservational_patient_registrySponsorFudan UniversityRan2026 to 2028Enrolled200ConditionsColorectal Liver MetastasesArmsgene sequencing, observational study
3 · Its place in the literature

Who cites it

1,533 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Prognostic value of postoperative circulating tumor DNA for recurrence-free survival in resected non-small cell lung cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Article
  14. Liquid biopsy in modern medicine: advancing diagnostics from molecular insights to clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  15. Review
  16. Applications of circulating tumor DNA in unresectable and advanced non-small cell lung cancer immunotherapy: from stratification to therapeutic guidance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  17. Review
  18. Review
  19. Review
  20. Article

1,473 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jonathan C M WanCancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
Charles MassieCancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
Javier Garcia-CorbachoClinical Trials Unit, Clinic Institute of Haematological and Oncological Diseases, Hospital Clinic de Barcelona, IDIBAPs, Carrer de Villarroel, 170 Barcelona 08036, Spain.
Florent MouliereCancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
James D BrentonCancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
Carlos CaldasCancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
Simon PaceyCancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK.
Richard BairdCancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK.
Nitzan RosenfeldCancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.

Funding

Cancer Research UK 15601Cancer Research UK 16942Cancer Research UK 20240Cancer Research UK 22905Cancer Research UK A11906Cancer Research UK A15601Cancer Research UK A20240
6 · The paper itself

Abstract

Improvements in genomic and molecular methods are expanding the range of potential applications for circulating tumour DNA (ctDNA), both in a research setting and as a 'liquid biopsy' for cancer management. Proof-of-principle studies have demonstrated the translational potential of ctDNA for prognostication, molecular profiling and monitoring. The field is now in an exciting transitional period in which ctDNA analysis is beginning to be applied clinically, although there is still much to learn about the biology of cell-free DNA. This is an opportune time to appraise potential approaches to ctDNA analysis, and to consider their applications in personalized oncology and in cancer research.

Indexed as

BiopsyBiomarkers, TumorClonal EvolutionDNA, NeoplasmEarly Detection of CancerErbB ReceptorsHumansMutationNeoplasmsNeoplasm StagingPrecision MedicineBiomarkers, TumorDNA, NeoplasmErbB Receptors

Identifiers

PMID28233803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.